Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Next Previous
Trial Profile

A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Rucaparib (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms ARIANES

Most Recent Events

  • 01 Dec 2025 Actual primary completion date is 25 Jan 2023.
  • 01 Dec 2025 Status changed from suspended to discontinued because of the bankruptcy of study partner Clovis.
  • 30 Apr 2025 Results assessing multi-omics analysis on sequential patient samples, including single-cell RNA + T-cell receptor sequencing (scRNA+TCR-Seq) and bulk RNA-Seq on sequential tumor biopsies, concomitant plasma proteomics, and whole exome sequencing, presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top